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Abstract
The succinate dehydrogenase consists of only four subunits, all nuclearly encoded, and is part of both the respiratory chain
and the Krebs cycle. Mutations in the four genes encoding the subunits of the mitochondrial respiratory chain succinate
dehydrogenase have been recently reported in human and shown to be associated with a wide spectrum of clinical
presentations. Although a comparatively rare deficiency in human, molecularly defined succinate dehydrogenase deficiency
has already been found to cause encephalomyopathy in childhood, optic atrophy or tumor in adulthood. Because none of the
typical housekeeping genes encoding this respiratory chain complex is known to present tissue-specific isoforms, the tissue-
specific involvement represents a quite intriguing question, which is mostly addressed in this review. A differential
impairment of electron flow through the respiratory chain, handling of oxygen, and/or metabolic blockade possibly
associated with defects in the different subunits that can be advocated to account for tissue-specific involvement is
discussed. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Complex II (CII; succinate^ubiquinone oxidore-
ductase (SQR); EC 1.3.5.1) is composed of four sub-
units, all of them being encoded by nuclear DNA [1].
Two of these subunits form the succinate dehydroge-
nase (SDH): the largest subunit, a £avoprotein of 70
kDa (Fp; SDH A) containing the putative active site
and the covalently bound FAD moiety of the en-
zyme, and the iron^sulfur protein (Ip; SDH B, 30
kDa) subunit carrying three dissimilar iron-clusters,
[2Fe^2S]2;1, [4Fe^4S]2;1, and [3Fe^4S]1;0[2]. The
SDH is anchored to the membrane by two additional
subunits, C and D (15 and 12.5 kDa respectively),
which contain a single heme group and the ubiqui-
none (UQ) binding sites (Fig. 1). In addition to these
structural subunits, a number of accessory factors
unknown in human are necessary for the assembly
and maintenance of the active enzyme complex.
CII is part of both the tricarboxylic acid cycle and
the mitochondrial respiratory chain [1]. It catalyzes
the oxidation of succinate to fumarate and transfers
the electrons to the UQ pool of the respiratory chain
(Fig. 1). While under most conditions electrons are
subsequently directed to oxygen allowing for ATP
synthesis, reverse electron £ow from succinate to
NAD might also occur in intact tissues (e.g. kidney,
liver) favored by low pO2 [3], possibly playing a role
in ketogenesis in liver. In keeping with this, a high
CII activity compared with the activity of the respi-
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ratory chain cytochrome segment (CIII^CIV) has
been observed in human liver and kidney tissues as-
sociated with comparatively high SDH mRNA levels
[4].
CII defects are relatively rare compared to other
respiratory chain de¢ciencies, yet they are associated
with a wide spectrum of clinical phenotypes, ranging
from encephalomyopathy in childhood to optic atro-
phy or tumor formation in adulthood [5]. Succinate
cytochrome c reductase de¢ciency and/or SDH activ-
ity impairment has been described in a handful of
patients in the last 20 years, associated with progres-
sive encephalomyopathy with dementia, myoclonic
seizure and short stature [6], Kearns^Sayre syndrome
with conduction defects [7], myopathy and encepha-
lopathy [8], isolated hypertrophic cardiomyopathy
[9], hypertrophic cardiomyopathy plus skeletal
muscle myopathy [10] generalized muscle weakness
and easy fatigability [11]. The molecular bases of
these de¢ciencies have not been elucidated for most
cases. However, in a few cases, mutations have been
identi¢ed in the genes encoding CII subunits, result-
ing in a wide variety of clinical presentations [12^16].
With none of these proteins being known to present
isoforms and all being ubiquitously expressed, the
tissue-speci¢c involvement inferred from the various
clinical presentations remains a puzzling question. In
addition to isolated CII de¢ciency, a generalized de-
¢ciency of Fe^S cluster-containing proteins, includ-
ing the SDH, has been reported in Friedreich’s ataxia
due to an oxidative stress caused by a decreased fra-
taxin content of the mitochondria [17]. As these cen-
ters represent a privileged target for superoxides, it
can be predicted that similar damages, involving the
SDH, will be progressively reported in a number of
situations of oxidative stress.
This review is mostly focused on the recent pro-
gresses made in the identi¢cation of the gene muta-
tions associated with CII defects. The strikingly vary-
ing biochemical and clinical consequences of these
mutations are discussed.
2. Mutations in SDH A encoding the Fp subunit
Fluorescent in situ hybridization and pulse-¢eld
gel electrophoresis analysis demonstrated that SDH
A is duplicated in the human genome (5p15; 3q29)
[12]. Expression studies on human/hamster somatic
cell hybrids showed that only the chromosome 5
gene is expressed [12]. The genomic structure of the
two SDH A genes has been determined and sequence
analysis of the two SDH A copies made it possible to
identify a 1-bp deletion creating a frame shift in the
3q29 copy, con¢rming that this copy is actually a
pseudogene [14]. The 5p15 gene comprises 15 exons
extending over 38 kb encoding a 664-amino acid
protein showing 95% homology with its bovine coun-
terpart [18]. Two cDNA sequences with speci¢c poly-
morphisms have been simultaneously described for
the 5p15-encoded Fp subunit, corresponding to two
di¡erent haplotypes [18,19].
The ¢rst reported nuclear gene mutation causing a
respiratory chain defect was a point mutation in the
gene encoding the SDH Fp subunit [12]. The muta-
tion was identi¢ed in two sibs presenting Leigh syn-
drome and SDH de¢ciency [20]. The patients were
homozygous for an Arg544Trp substitution in a con-
served domain of the protein [12]. Both consangui-
neous parents were found heterozygous for the mu-
tation. The deleterious e¡ect of the Arg544Trp
substitution on the catalytic activity of the enzyme
was assessed in a SDH-negative mutant yeast strain
transformed with wild-type or mutant Fp cDNA. In
a second patient with Leigh syndrome, SDH de¢-
ciency and compound heterozygous mutations in
the SDH Fp gene were afterward reported [14].
Fig. 1. A schematic view of the respiratory chain CII. Featuring
the four CII subunits with their various alternative symbols, the
scheme shows the SDH consisting of the Fp and Ip subunits
anchored to the mitochondrial inner membrane by the subunits
C and D. Stabilized semi-quinone species feed electrons to the
UQ (Q) pool.
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The patient, born to unrelated parents, was found
heterozygous for an Ala524Val substitution inherited
from the father. Transfection of the corresponding
mutant cDNA into Fp-de¢cient cells failed to restore
normal SDH activity, con¢rming the deleterious ef-
fect of this mutation. The second allele, inherited
from the mother, carried an A-to-C substitution,
changing the methionine translation initiation codon
to a leucine. Instability of this mutant transcript was
demonstrated by quanti¢cation (10% residual tran-
script).
A third case of SDH A mutation has been recently
documented in two sisters with partial CII de¢ciency
and late-onset neurodegenerative disease with pro-
gressive optic atrophy, ataxia, and myopathy [21].
The a¡ected members of this family were shown to
carry a heterozygous Arg408Cys substitution in a
highly conserved region of the protein [13]. The
equivalent mutation in Escherichia coli generated an
inactive enzyme unable to bind £avin adenine dinu-
cleotide covalently. No mutation in the other allele
was identi¢ed and this was claimed to be compatible
with the 50% residual CII and SDH activity found in
these patients. To date, no additional mutations have
been reported in the SDH A encoding the Fp sub-
unit.
3. Mutations in SDH B encoding the Ip subunit
The gene encoding the human SDH Ip subunit
maps to chromosome 1p36.1-p35 [22,23]. It encodes
a 252-amino acid protein showing 94% homology
with its bovine heart counterpart. The complete ge-
nomic sequence was described afterwards, consisting
of eight exons within approximately 40 kb [24].
Very recently, gene mutations in the SDH B have
been shown to cause tumor formation in familial
paraganglioma (PGL) and familial pheochromocyto-
ma [25], following the description of causative muta-
tions in SDH C and D in patients with this condition
(see below).
PGLs are vascularized, neural crest-derived tumors
of the sympathetic paraganglia, being mostly located
in the head and the neck, i.e. carotid bifurcation,
skull base or middle ear [15]. The carotid body is
the most common tumor site. This highly vascular
small organ is localized at the bifurcation of the
common carotid artery and is a chemoreceptive or-
gan that senses oxygen levels in the blood. In familial
PGL, cellular hyperplasia/anaplasia is observed in
the tumor in the absence of any hypoxic stimulus.
Pheochromocytomas are catecholamine-producing
tumors that cause excess release of the two hormones
epinephrine and norepinephrine, which regulate
heart rate and blood pressure. The vast majority of
pheochromocytomas are observed in the adrenal me-
dulla (about 90% of the cases). Due to their location
in sympathetic paraganglia, the other 10% can be
classi¢ed as PGL.
Hereditary PGL is transmitted with incomplete
and age-dependent penetrance and is genetically het-
erogeneous. PGL has been mapped to three loci,
PGL1 at 11q22.3-23.1, PGL2 at 11q13.1, and
PGL3 which does not segregate with either of the
loci at 11q [26^28]. PGL1 is an autosomal dominant
disease with incomplete penetrance when transmitted
through the father, whereas no disease occurs when
maternally transmitted, suggesting genomic imprint-
ing [15].
A loss of CII activity presumably due to damage
to the SDH B-associated iron^sulfur clusters has also
been reported in Friedreich’s ataxia [17] and in one
familial case of Ip-de¢ciency presented with myopa-
thy [29].
4. Mutations in SDH anchoring subunits
SDH C and D are respectively the large and the
small anchoring subunits of the CII (140 and 103
amino acids long). SDH C gene comprises six exons
and ¢ve introns extending over 35 kb [30] and has
been mapped to chromosome 1q21 [31]. SDH D gene
has been mapped to chromosome 11q23 by £uores-
cence in situ hybridization and comprises four exons
extending over more than 18 kb [31]. Noticeably,
while both the Fp and the Ip subunits are highly
conserved through evolution, SDH C and D show
little similarity to their respective other species coun-
terparts. It has also been stated that there are multi-
ple SDH C genes or pseudogenes based on Southern
blot analyses [32]. The identi¢cation of two of
these as pseudogenes has been described afterwards
[30].
Sequencing the SDH D gene made it possible to
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identify missense mutations a¡ecting conserved ami-
no acids and nonsense mutations in several families
showing signi¢cant linkage to PGL1 locus mapped
to chromosome 11q22.3-23.1 in a 11.5 Mb critical
interval between D11S1968 and D11S1347 contain-
ing the SDH D gene [15]. These mutations were het-
erozygous in both a¡ected individuals and healthy
carriers. To account for the lack of maternal disease
transmission in PGL1, allele-speci¢c expression of
the SDH D gene was looked for. Biallelic expression
was observed in all tissues investigated in both af-
fected and carrier individuals, denoting that SDH D
was not located in an imprinted genomic domain
[15]. The imprinted inheritance pattern in PGL1 re-
mains therefore to be explained, but the monoallelic
expression of SDH D might be con¢ned to the para-
ganglionic cells. On the other hand, loss of hetero-
zygosity with exclusive loss of the normal maternal
chromosome at 11q23 has been frequently observed
in PGL1 tumors. In all cases studied, the mutated
SDH D allele was retained in the tumor cells, while
the normal allele was completely lost. The germ-line
loss of function mutations of the paternal allele and
the somatic loss of the maternal allele suggest that
SDH D acts as a tumor suppressor gene. Mutations
in SDH D were also identi¢ed in sporadic extra-adre-
nal pheochromocytoma [33].
The suggestion that SDH genes may act as tumor
suppressor genes was strongly reinforced by the ob-
servation that mutations in a second SDH gene,
SDH C, were the underlying cause of autosomal
dominant PGL3 [16]. Indeed, a G-to-A transition
in the exon 1 of the SDH C has been shown to
destroy the start codon at nucleotide position 958
in a patient with familial PGL3 [16]. Again the mu-
tated SDH C allele was retained in the tumor cells,
while the normal allele with wild-type SDH C was
lost.
Taken together, these data support the view that
SDH B, C and D genes are tumor suppressor genes.
Based on the phenotypic similarity between PGL tu-
mor and normal carotid body submitted to chronic
hypoxia, it may be hypothesized that these subunits
are critical components of the oxygen-sensing system
of the paraganglionic tissue, and that their loss ac-
tually results in oxidative stress, chronic hypoxic
stimulation and cellular proliferation [15]. Interest-
ingly enough, a mutation in the mev-1(kn1) gene of
Caenorhabditis elegans, the orthologue of the mam-
malian SDH C gene, causes oxidative stress and pre-
mature ageing [34]. The mutation has been shown to
compromise electron transfer between the SDH, still
present in the mitochondria, and the UQ pool, pre-
sumably resulting in an increased superoxide produc-
tion by SDH.
As oxygen free radicals are believed to play a key
role in both cell proliferation and apoptosis, and as
the mitochondrial MnSOD gene has been shown to
act as a tumor suppressor gene [35], it is tempting to
hypothesize that superoxide overproduction resulting
from SDH C or D mutations triggers tumor forma-
tion because of preserved catalytic activity of the
SDH A and B (Fig. 2). However, it remains to
show that the lack (or decrease) of either SDH C
or D anchoring subunit is still compatible with the
SDH assembly and function as proposed in the nem-
atode. In addition, the recent report that mutations
in SDH B gene also cause familial pheochromocyto-
Fig. 2. Di¡erences in the predictable consequences of mutations
a¡ecting either the SDH or the anchoring subunits C and D.
A: Mutations in the SDH subunits (Fp or Ip) should tend to
reduce Krebs cycle activity and consequently mitochondrial
ATP synthesis. Reduced electron £ow through the SDH should
decrease SDH component reduction and not result in a major
increase of superoxide production. Noticeably, some particular
mutation could still favor an over-reduction of a given SDH
component (e.g. £avin), resulting in superoxide production. B:
Mutations in SDH C or D by causing reduction of the electron
£ow to the UQ pool will favor reduction of the several SDH
components and possibly result in higher superoxide produc-
tion. This latter may cause oxidative stress and favor tumor
formation in patients.
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ma and paraganglioma does not support the view
that an active superoxide production triggered by a
non-anchored SDH is the actual pathogenic mecha-
nism underlying this condition. Whatever the subunit
considered, the percent of residual SDH activity as-
sociated with the various types of mutation may
rather be the key feature and should be urgently
measured in the di¡erent cases.
5. Clinical presentations associated with CII defect
A mutation in the CII Fp subunit was the ¢rst
mutation identi¢ed in a nuclear gene encoding a res-
piratory chain component [12]. Because the nuclear
genes encoding the respiratory chain subunits are
typical housekeeping genes, it was initially thought
that a reduced clinical spectrum would be associated
with mutations in these genes [36]. However, as ob-
served, for example, in the case of the mutations
a¡ecting respiratory chain CIV assembly genes, vary-
ing clinical features may result from mutations in
genes that are functionally closely related [5]. This
is clearly the case for CII de¢ciencies, the disease
causing mutations lying in the genes encoding CII
subunits or in yet unknown genes. This might well
be related to the several functions contributed by CII
proteins in either the respiratory chain ATP synthesis
and oxygen handling, or the Krebs cycle and possi-
bly the organ-speci¢c mitochondrial metabolism.
First, as in the case of most de¢ciencies a¡ecting
the di¡erent respiratory chain complexes, hampering
CII activity should ultimately result in reduced ATP
synthesis. Accordingly, it has been shown that pa-
tients’ cultured skin ¢broblasts harboring a mutation
in the CII Fp gene cannot survive upon glucose with-
drawing from culture medium that turns down ATP-
generating glycolysis [37]. In keeping with this, neu-
romuscular symptoms associated with CII de¢cien-
cies (myopathy and encephalopathy) are typical fea-
tures associated with respiratory chain de¢ciencies
a¡ecting other respiratory chain complexes [5]. Sim-
ilarly, a hypertrophic cardiomyopathy, as the one
reported in association with few cases of CII de¢-
ciency (2 cases on more than 3000 investigations in
patients at risk in our experience), is frequently ob-
served as the result of a respiratory chain dysfunc-
tion [5]. However, it remains to be explained why a
hypertrophic cardiomyopathy is not a consistent fea-
ture in CII de¢ciencies. Noticeably, sequencing of the
four genes encoding CII subunits in patients with
isolated hypertrophic cardiomyopathy and SDH de-
¢ciency failed to reveal any mutation (unpublished
data). Finally, optic atrophy, as reported in two
adult patients with SDH de¢ciency and heterozygous
mutations in SDH Fp gene, is not a rare feature in
mitochondrial diseases [13]. However, its unique oc-
currence in these two patients with partial SDH de-
¢ciency is quite puzzling, since heterozygous parents
of patients harboring other deleterious mutations in
any of the four genes encoding SDH subunits do not
present optic atrophy.
The causative association of respiratory chain de-
fect and tumor formation is amazing, even if mito-
chondria have been long claimed to be indirectly in-
volved in tumor processes. The handling of oxygen
for the bene¢t of the cell is a quite dangerous task
ensured by the respiratory chain and it appears that
CII (SDH?) is a privileged location for superoxide
production. A speci¢c role of CII in generating/elim-
inating superoxides might therefore account for SDH
B, C and D, acting as tumor suppressor genes.
6. Conclusion
The recent discovery of tumor-causing mutations
in the SDH B, C and D genes has further widened
the already broad spectrum of diseases primarily
caused by mutations in genes encoding mitochon-
drial respiratory chain proteins. The particular case
of CII de¢ciencies perfectly illustrates the complexity
of these diseases that can be revealed in childhood or
adulthood, that can be or not neuromuscular dis-
eases, and that can involve quite di¡erent organs
for yet unknown reasons. Beside the four structural
genes involved in CII, a yet undetermined number
of genes might be involved in CII assembly. Based
on what has been observed for other respiratory
chain complexes, mutations in assembly genes quite
frequently cause respiratory chain dysfunction and
it can be predicted that this will stand true as
well for CII defect. Again, mutations in these
genes can be at the origin of newly described diseases
or of ‘old’ diseases of yet unknown mitochondrial
origin.
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